Angélique Fan

Angélique Fan

Auto-generated profile, based on publicly available information

Angélique Fan

Rheumatology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 August 2025 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
FFFrançoise FAYET
Françoise FAYET
AFAngélique Fan
Angélique Fan
Bruno PereiraBruno Pereira
Bruno Pereira
CLCéline Lambert
Céline Lambert
LPLaurent Perron
Laurent Perron
MSMartin Soubrier
Martin Soubrier

6 March 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
AFAngelique Fan
Angelique Fan
CLCéline Lambert
Céline Lambert
JSJeremie Sellam
Jeremie Sellam
RCRoland Chapurlat
Roland Chapurlat
HMHubert Marotte
Hubert Marotte
SMSylvain Mathieu
Sylvain Mathieu
Introduction It is common for finger pain in hand osteoarthritis (HOA) to display a neuropathic component. Non-steroidal anti-inflammatory drugs (NSAIDs) and conventional analgesics are not very effective in relieving this neuropathic-like pain. Capsaicin, a compound extracted from chilli peppers, is approved for the management of localised neuropathic pain. However, the effectiveness of an 8% capsaicin transdermal patch has never been tested in HOA patients with neuropathic-like pain in a randomised setting. In this study, we aimed to compare the 60-day (D60) efficacy of a transdermal application of capsaicin 8% versus a control (very low-dose capsaicin at 0.04%) on hand pain in patients with painful digital osteoarthritis with a neuropathic-like pain component. Methods and analysis CADOR (CApsaicin in neuropathic-like pain in Digital Osteoarthritis: a Randomised trial) is a multicentre, randomised, controlled, double-blind, two parallel group, phase 3 clinical trial. Eligible patients have HOA according to the American College of Rheumatology criteria and at least Kellgren-Lawrence grade≥2, with neuropathic-like pain (‘Douleur neuropathique en 4 questions’ (DN4) score≥4/10 and pain intensity≥40/100 mm). At Day 0, 120 patients will be randomised (1:1) to receive a single 30 min topical application of either capsaicin 8% transdermal patch (experimental group) or capsaicin 0.04% transdermal patch (control group). The primary outcome is pain intensity in the fingers over the past 48 hours at Day 60, measured with a Visual Analogue Scale (VAS) ranging from 0 to 100 mm. Secondary outcomes are functional disability, quality of life, anxiety and depression, the patient’s global impression of improvement, use of analgesics and NSAIDs and the safety of capsaicin. At visit D60, patients who still have finger pain≥40/100 mm on the VAS will receive, if they wish a single 30 min topical application of capsaicin 8% transdermal patch (not blinded). The efficacy of two transdermal applications of capsaicin (either two applications of 8% patch in the experimental arm or one application of 0.04% and one application of 8% in the control arm) will be assessed on Day 120. Ethics and dissemination Ethics approval was obtained from the French Health Authorities (Comité de protection des Personnes SUD EST V and Agence Nationale de Sécurité du Médicament) on 23 May 2024 in accordance with European Regulation n°536/2014 of 16 April 2014 (ref: 2024-511159-16-00) before participant enrolment. Trial registration number ClinicalTrials.gov: NCT06444919.


15 September 2022 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
FFFrançoise FAYET
Françoise FAYET
NDNatacha Darmant
Natacha Darmant
MRMalory Rodere
Malory Rodere
AFAngélique Fan
Angélique Fan
MCMaryline Chalmeton
Maryline Chalmeton
MDMartine Duclos
Martine Duclos
Chronic inflammatory rheumatism (CIR), especially rheumatoid arthritis (RA) and spondyloarthritis (SpA), can be improved with physical activity. Despite recommendations of regular physical activity,1 most patients with CIR are physically inactive.2

26 November 2022 in Joint Bone Spine
Verified
Journal Article
Open access
AFAngelique Fan
Angelique Fan
BGBaptiste Glace
Baptiste Glace
Bruno PereiraBruno Pereira
Bruno Pereira
SMSandrine Malochet-Guinamand
Sandrine Malochet-Guinamand
MCMarion Couderc
Marion Couderc
JDJean-Jacques Dubost
Jean-Jacques Dubost
Post-traumatic stress disorder (PTSD) may be a risk factor for the development of rheumatoid arthritis (RA). No data are available in spondyloarthritis (SpA). The aim of the present study was to investigate the frequency of traumatic events and PTSD in patients with SpA and its different phenotypes and to compare the results to patients with non inflammatory rheumatic disease and RA patients. This was an observational, cross-sectional and bi-centric study. Participants were patients diagnosed with SpA, non-inflammatory rheumatic or autoimmune disease (controls), or RA. Traumatic events were identified by the brief trauma questionnaire (BTQ). PTSD was defined as the presence of a traumatic event and ≥4 symptoms on the short PTSD checklist scale. Among 1389 participants, 510 patients were diagnosed with SpA (167 ankylosing spondylitis, 140 psoriatic arthritis, 130 non-radiographic-axial SpA, and 51 peripheral SpA), 365 with non-inflammatory rheumatic disease and 514 patients with RA. The frequency of trauma in SPA patients was 33.7%, of which 30.5% in AS, 30.7% in PsA, 37.7% in nr-axSpA and 41.2% in peripheral SpA (P=NS). The prevalence of PTSD in SPA patients was 4.9%, (of which 3.6% in AS, 2.9% in PsA, 6.2% in nr-axSpA and 7.8% in peripheral SpA [P=NS]) and was not significantly different from the controls (after IPTW 4.8% vs. 6.7%). The frequency of trauma and PTSD was also comparable between RA and controls and between SPA and RA. Traumatic events and PTSD occurring prior to diagnosis is as rare in SpA as in non-inflammatory rheumatic diseases and RA.